JP2003526626A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526626A5
JP2003526626A5 JP2001514280A JP2001514280A JP2003526626A5 JP 2003526626 A5 JP2003526626 A5 JP 2003526626A5 JP 2001514280 A JP2001514280 A JP 2001514280A JP 2001514280 A JP2001514280 A JP 2001514280A JP 2003526626 A5 JP2003526626 A5 JP 2003526626A5
Authority
JP
Japan
Prior art keywords
emphysema
medicament
manufacture
treatment
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001514280A
Other languages
English (en)
Japanese (ja)
Other versions
JP3961827B2 (ja
JP2003526626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2000/007091 external-priority patent/WO2001009076A2/en
Publication of JP2003526626A publication Critical patent/JP2003526626A/ja
Publication of JP2003526626A5 publication Critical patent/JP2003526626A5/ja
Application granted granted Critical
Publication of JP3961827B2 publication Critical patent/JP3961827B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001514280A 1999-08-02 2000-07-25 新規な選択的レチノイドアゴニスト Expired - Fee Related JP3961827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99115223.2 1999-08-02
EP99115223 1999-08-02
PCT/EP2000/007091 WO2001009076A2 (en) 1999-08-02 2000-07-25 Retinoids for the treatment of emphysema

Publications (3)

Publication Number Publication Date
JP2003526626A JP2003526626A (ja) 2003-09-09
JP2003526626A5 true JP2003526626A5 (enExample) 2004-12-24
JP3961827B2 JP3961827B2 (ja) 2007-08-22

Family

ID=8238709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001514280A Expired - Fee Related JP3961827B2 (ja) 1999-08-02 2000-07-25 新規な選択的レチノイドアゴニスト

Country Status (18)

Country Link
US (3) US6528677B1 (enExample)
EP (1) EP1206436B1 (enExample)
JP (1) JP3961827B2 (enExample)
KR (1) KR100466730B1 (enExample)
CN (1) CN1166618C (enExample)
AR (1) AR024998A1 (enExample)
AT (1) ATE279386T1 (enExample)
AU (1) AU772551B2 (enExample)
BR (1) BR0012951A (enExample)
CA (1) CA2386793C (enExample)
DE (1) DE60014928T2 (enExample)
DK (1) DK1206436T3 (enExample)
ES (1) ES2228587T3 (enExample)
MX (1) MXPA02000828A (enExample)
PT (1) PT1206436E (enExample)
TR (1) TR200200263T2 (enExample)
WO (1) WO2001009076A2 (enExample)
ZA (1) ZA200200516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US7914437B2 (en) * 2005-02-04 2011-03-29 Ams Research Corporation Transobturator methods for installing sling to treat incontinence, and related devices
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP3067054B1 (en) 2007-09-10 2020-12-30 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
CA2856703A1 (en) * 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
WO2017087608A1 (en) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー, インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
KR20200053481A (ko) 2017-07-24 2020-05-18 비타이 파마슈티컬즈, 엘엘씨 RORγ의 억제제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87821A1 (fr) * 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Similar Documents

Publication Publication Date Title
JP2003526626A5 (enExample)
JP2003503454A5 (enExample)
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
JP2007514005A5 (enExample)
JP2005519891A5 (enExample)
JP2005500357A5 (enExample)
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO20033594L (no) Fenetanolamin-derivater for behandling av luftveissykdommer
JP2004529078A5 (enExample)
JP2004523498A5 (enExample)
JP2004532810A5 (enExample)
HUS1400011I1 (hu) Új gyógyszer krónikus elzáródásos tüdõbetegség kezelésére
JP2002532112A5 (enExample)
JP2005526147A5 (enExample)
JP2005507892A5 (enExample)
JP2008513510A5 (enExample)
PL364086A1 (en) Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
JP2006506499A5 (enExample)
JP2002542248A5 (enExample)
JP2008515980A5 (enExample)
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
JP2008513426A5 (enExample)
NO20012831D0 (no) Diazepinoindoler for behandling av kronisk obstruktiv lungesykdom
JP2008513427A5 (enExample)
DE602006012332D1 (de) Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma